Skip Navigation


Rheumatology Advance Access originally published online on October 31, 2006
Rheumatology 2006 45(12):1573-1575; doi:10.1093/rheumatology/kel365
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/12/1573-a    most recent
kel365v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eklund, K. K.
Right arrow Articles by Leirisalo-Repo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eklund, K. K.
Right arrow Articles by Leirisalo-Repo, M.
Related Collections
Right arrow Spondylarthropathies
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients

K. K. Eklund, A. Remitz1, H. Kautiainen2, S. Reitamo1 and M. Leirisalo-Repo

Department of Internal Medicine, Division of Rheumatology, and 1Department of Dermatology, Helsinki University Central Hospital, Helsinki, Finland and 2Rheumatism Foundation Hospital, Heinola, Finland

Correspondence to: Kari Eklund, Helsinki University Central Hospital, Kasarmikatu 11-13, 00130 Helsinki, Finland. E-mail: kari.eklund@HUS.fi

The first 10% of the full text of this article appears below.

SIR, Current conventional anti-rheumatic therapies show limited efficacy in the treatment of spondyloarthritides. Imatinib mesylate (Gleevec®) is a relatively well-tolerated [1] selective inhibitor of tyrosine kinases, which include platelet-derived growth factor receptor, c-kit and macrophage colony-stimulating factor receptor [2]. All of these kinases have been implicated in the pathogenesis of inflammatory synovitis. Recent findings have suggested that imatinib may possess anti-rheumatic activity [3–4]. Therefore, we studied whether imatinib mesylate could have anti-rheumatic activity in the treatment of spondyloarthritides.

. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?